March 29 (Reuters) - Antibe Therapeutics Inc ATE.V :
* ANTIBE THERAPEUTICS ANNOUNCES COMMENCEMENT OF PHASE 2B DOSE-RANGING, EFFICACY STUDY FOR LEAD DRUG, ATB-346
* ANTIBE THERAPEUTICS - STUDY IS EXPECTED TO HAVE A TOP-LINE DATA READ-OUT THIS SUMMER